On December 2, 2009, the Arrow Group was acquired by Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading U.S. based specialty pharmaceutical company with over $3 billion in annual revenues. The acquisition creates a global pharmaceutical company with operations in many of the world's established and growing markets, and a strong product portfolio and pipeline; creating significant opportunities for long-term growth.
To learn more about Watson Pharmaceuticals, Inc. please click either the link button to the left of the page or go to www.watson.com
During it's relatively short history, Arrow UK has managed to launch in excess of 275 products.
They cover a wide range of therapeutic areas
including standard and modified release presentations of
tablets and capsules. The range does not stop there however and includes specialised presentations of creams,
ointments, drops, suspensions, syrups, solutions and suspensions for nebulisation.
With
a large emphasis within the Group being concentrated on the development of future patent
expiring molecules. Arrow in the UK has benefited from the launch of numerous
products on day 'one' following patent expiry. This continues to be the
key strategy for the management team, many of whom have extensive experience
of the generics industry.
With
a culture of being first to market, a commitment to an ever
expanding portfolio and a dedication to
delivering a fast and reliable service to our customers, it's no wonder Arrow
goes from strength to strength.
To find out more about Arrow
Generics please search the website further, or contact us via the web page.
